Robert B. Belshe, M.D. -Clinical Advisory Board Chair
Dr. Belshe is the Diana and J. Joseph Adorjan Endowed Professor of Infectious Diseases and Immunology, Emeritus at Saint Louis University. He is an expert in clinical trial design and execution, and his laboratory focuses on antibody responses to viral vaccines, including influenza, RSV and vaccinia. Development of other formulations of influenza vaccine including intradermal vaccine, high dose vaccine, quadrivalent vaccine, and pandemic vaccine have been influenced by his work. He was the editorialist for the NEJM regarding what to expect from the 2009 H1 pandemic virus. He chaired the NIH/industry cooperative Phase 3 pivotal licensing studies on live attenuated influenza vaccine, he conducted the vaccinia dilution studies for the NIH biodefense initiative, and most recently he chaired the NIH and GSK Herpevac Trial for Women.
Kathleen L. Coelingh, Ph.D.
Dr. Coelingh was Senior Director, Medical Affairs at MedImmune, the biologics unit of AstraZeneca. Prior to that, while at the NIH she led the team that discovered the mouse monoclonal antibody that neutralizes Respiratory Syncytial Virus (RSV), which was humanized at MedImmune and is licensed for prevention of serious lower respiratory tract disease caused by RSV in high-risk pediatric patients.
Harry Greenberg, M.D.
Dr. Greenberg is an Associate Dean for Research at Stanford University School of Medicine and the Co-Director of Spectrum, the Stanford NIH funded CTSA. He is also the Joseph D. Grant Professor of Medicine and Microbiology and Immunology at Stanford Medical School. He is an author of over 450 publications and is the recipient of many honorary awards. Most recently Dr. Greenberg was recognized as the Recipient of the Gold Medal Award from Columbia College of Physicians and Surgeons for Distinguished Achievements in Research and by the American Gastroenterological Association for Distinguished Achievements in Basic Science. Dr. Greenberg previously served as Chairperson of the FDA VRBPAC and as President of the American Society of Virology. He spent 2 years in industry working as the Chief Scientific Officer at Aviron (then MedImmune Vaccines) helping to develop FluMist.
Yoshihiro Kawaoka, DVM, Ph.D., Co-Founder
Dr. Kawaoka has been studying influenza viruses for more than 30 years. His work has helped to answer key questions in influenza virus research such as how influenza viruses cause disease, why certain types of influenza viruses are found in humans while other types are found only in birds, and how influenza viruses change over time. In 2006, Dr. Kawaoka was awarded the prestigious Robert Koch Award for his innovative research in the field of influenza virology. He currently maintains joint appointments and highly active influenza research programs at both the University of Wisconsin-Madison and the University of Tokyo.
Gabriele Neumann, Ph.D., Co-Founder
Dr. Neumann brings both significant academic and industry experiences to FluGen, Inc. She is a trained molecular virologist with more than 25 years working with the influenza virus. Her graduate studies in Germany were instrumental in the breakthrough of “reverse genetics” during her postdoctoral fellowship in Dr. Kawaoka’s research group. For this accomplishment Dr. Neumann was awarded the Loeffler-Frosch Award in 2000. She also spent time in industry with Wyeth (now Pfizer) where she worked on the development of FluMistTM/ CAIV-T. In 2002, she rejoined Dr. Kawaoka’s research group, where she currently holds the position of Research Professor/Distinguished Scientist.